Investment Fund, Lp Njtc Net Worth

The estimated Net Worth of Investment Fund, Lp Njtc is at least $5.3 Million dollars as of 31 December 2008. Investment Njtc owns over 124,281 units of Cytosorbents Corp stock worth over $4,870,218 and over the last 16 years Investment sold CTSO stock worth over $427,527.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Investment Njtc CTSO stock SEC Form 4 insiders trading

Investment has made over 1 trades of the Cytosorbents Corp stock since 2008, according to the Form 4 filled with the SEC. Most recently Investment sold 124,281 units of CTSO stock worth $427,527 on 31 December 2008.

The largest trade Investment's ever made was selling 124,281 units of Cytosorbents Corp stock on 31 December 2008 worth over $427,527. On average, Investment trades about 124,281 units every 0 days since 2008. As of 31 December 2008 Investment still owns at least 4,870,218 units of Cytosorbents Corp stock.

You can see the complete history of Investment Njtc stock trades at the bottom of the page.

What's Investment Njtc's mailing address?

Investment's mailing address filed with the SEC is 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL, NJ, 08054.

Insiders trading at Cytosorbents Corp

Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, and Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.

What does Cytosorbents Corp do?

cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm"​ or "cytokine release syndrome"​ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents'​ purification technologies are based on biocompatible, highly porous polymer beads

Complete history of Investment Njtc stock trades at Cytosorbents Corp

Cytosorbents Corp executives and stock owners

Cytosorbents Corp executives and other stock owners filed with the SEC include:

• Phillip Chan,
  President, Chief Executive Officer, Director
• Vincent Capponi,
  Chief Operating Officer
• Kathleen Bloch,
  Chief Financial Officer
• Dr. Phillip P. Chan,
  CEO & Director
• Vincent J. Capponi M.S., MS,
  Pres & COO
• Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.,
  Chief Medical Officer
• Kathleen P. Bloch CPA, M.B.A., MBA, CPA,
  CFO & Sec.
• Al Kraus,
  Independent Non-Executive Chairman of the Board
• Alan Sobel,
  Independent Director
• Edward Jones,
  Independent Director
• Michael Bator,
  Independent Director
• Dr. Robert H. Bartlett,
  Co-Chairman of Cardiac Surgery Advisory Board & Consultant
• Christopher Cramer,
  VP of Bus. Devel.
• Dr. Christian Steiner M.D.,
  Exec. VP of Sales & Marketing
• Terri Anne Powers M.B.A.,
  VP of Investor Relations & Corp. Communications
• Peter J Mariani,
  Chief Financial Officer
• Eric R. Mortensen,
  Chief Medical Officer
• Robert Hawes Bartlett,
  Chief Medical Officer
• Investment Fund, Lp Njtc,
  10% owner
• Joseph Rubin,
  Director
• Ronald Berger,
  Interim CFO
• James T. Gunton,
  Director
• Efthymios Deliargyris,
  Chief Medical Officer
• Jiny Kim,
  Director